Journal: Cancer discovery
This report describes a phase III study in HER2‑positive metastatic breast cancer evaluating tucatinib added to trastuzumab and pertuzumab as first‑line maintenance therapy after initial disease control.
Key points:
- Population: Patients with HER2‑positive metastatic breast cancer receiving first‑line maintenance therapy.
- Intervention: Tucatinib combined with trastuzumab and pertuzumab.
- Comparator: Placebo combined with trastuzumab and pertuzumab.
- Main outcome: The tucatinib triplet significantly improved progression‑free survival versus the antibody doublet alone.
- Context: The magnitude of PFS benefit is highlighted as being in the same general league as other recent impactful phase III advances in this space, specifically trastuzumab deruxtecan and palbociclib.
Overall, adding tucatinib to standard dual HER2 antibody maintenance appears to meaningfully delay disease progression in the first‑line metastatic setting, reinforcing the role of HER2‑targeted TKIs in combination with monoclonal antibody backbones.